FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation. Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health...
FORUS Therapeutics Inc. and PharmaEssentia Corporation have entered into an exclusive licensing agreement for the registration and distribution of BESREMi® (ropeginterferon alfa-2b) for the treatment of polycythemia vera (PV), in Canada. Under the terms of the...
FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas – including over 15 years in hematology and...
FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...
In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations...
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria: PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...
Recent Comments